Umecrine Cognition appoints Bruce Scharschmidt to board
Dr. Scharschmidt most recently served as Senior Vice President and Chief Medical & Development Officer at Hyperion Therapeutics (acquired by Horizon Pharma Inc. in 2015), where he was responsible for the development of glycerol phenylbutyrate (GPB, RAVICTI), and for the successful phase 2 trial of GPB for hepatic encephalopathy (HE).
Dr. Scharschmidt was the inventor/co-inventor on all Hyperion IP, a member of Hyperion’s roadshow team leading to its 2012 IPO, 2013 secondary offering and May 2015 sale to Horizon Pharma, to which he remains a consultant.
Previously, he held senior positions at Novartis, Chiron and the University of California, San Francisco (UCSF), where he was Professor of Medicine and Chief of Gastroenterology, helping launch the UCSF liver transplant program.
Dr. Scharschmidt was an NIH-funded investigator for two decades, is the author of more than 200 research and review articles and multiple issued and pending patents, and he also served as Associate Editor of Gastroenterology, Editor-in-Chief of the Journal of Clinical Investigation and President of the American Society for Clinical Investigation.
Board Certified in Internal Medicine and Gastroenterology, he was a member of the National Board of Directors of the American Liver Foundation from 2005-2013 and is currently a member of the External Advisory Board for the Clinical and Translational Science Program at Northwestern’s Feinberg School of Medicine, President of Northwestern’s Medical Alumni Board and member of the President’s Council Executive Committee for the J. David Gladstone Institute. ■